Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Asan Medical Center
Zai Lab (Hong Kong), Ltd.
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Shanghai Pharmaceuticals Holding Co., Ltd
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret
Institut Bergonié
Endeavor Biomedicines, Inc.
St. Jude Children's Research Hospital
Mario Negri Institute for Pharmacological Research
National Institutes of Health Clinical Center (CC)
AIDS Malignancy Consortium
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Institut Bergonié
Lytix Biopharma AS
Stanford University
Bayer
Maria Sklodowska-Curie National Research Institute of Oncology
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Institut Bergonié
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Emory University
Insel Gruppe AG, University Hospital Bern
Leap Therapeutics, Inc.
Masonic Cancer Center, University of Minnesota
Ipsen
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
Chipscreen Biosciences, Ltd.
National Institutes of Health Clinical Center (CC)
Zai Lab (Hong Kong), Ltd.
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Leiden University Medical Center
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Stanford University